Follow us on Twitter
twitter icon@FreshPatents


Immune Diseases patents

      

This page is updated frequently with new Immune Diseases-related patent applications.




 Method for generating t-cells compatible for allogenic transplantation patent thumbnailnew patent Method for generating t-cells compatible for allogenic transplantation
The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are characterized in that the expression of beta 2-microglobulin (b2m) and/or class ii major histocompatibility complex transactivator (ciita) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by dna cleavage the gene encoding b2m and/or ciita, or by using nucleic acid molecules which inhibit the expression of b2m and/or ciita.
Cellectis


 Ddx5 and associated non-coding rnas and modulation of th17 effector function patent thumbnailnew patent Ddx5 and associated non-coding rnas and modulation of th17 effector function
Methods for screening to identify agents capable of modulating ddx5 polypeptide activity are encompassed herein as are methods for using such agents to treat subjects afflicted with th17-mediated inflammatory conditions and autoimmune diseases including, without limitation, crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis and methods for using such agents to treat subjects afflicted with cancer.. .

 Antibody polypeptides that antagonize cd40 patent thumbnailnew patent Antibody polypeptides that antagonize cd40
Antibody polypeptides that specifically bind a novel epitope of human cd40 are provided. The antibody polypeptides do not exhibit cd40 agonist activity.
Domantis Limited


 Inhibitors of bruton's tyrosine kinase patent thumbnailnew patent Inhibitors of bruton's tyrosine kinase
Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


 Compound having selective ep2 agonist activity patent thumbnailnew patent Compound having selective ep2 agonist activity
A compound represented by general formula (i) wherein all symbols are as defined in the specification, a salt or n-oxide of the compound, or a solvate or prodrug of the compound or the salt or n-oxide has a selective ep2 agonist activity and is highly safe, and is therefore useful as a drug, especially as a therapeutic agent for ep2 receptor-related diseases including immune diseases, allergic diseases, neuronal death, dysmenorrhea, premature birth, miscarriage, baldness, ocular diseases, erectile dysfunction, arthritis, lung injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, bone diseases, cartilage injury and others.. .
Ono Pharmaceutical Co., Ltd.


 Benzazepine dicarboxamide compounds patent thumbnailnew patent Benzazepine dicarboxamide compounds
Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases patent thumbnailApoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Disclosed herein are compounds that inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.. .
Abbvie Inc.


 Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors patent thumbnailPyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
The present invention provides a heterocyclic compound having a tlr7, tlr9, tlr7/8, tlr7/9 or tlr7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof..
Takeda Pharmaceutical Company Limited


 Methods and compositions used in treating inflammatory and autoimmune diseases patent thumbnailMethods and compositions used in treating inflammatory and autoimmune diseases
Methods of treating neuroinflammation by administration of a selective protein c activator, such as recombinant human we thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation.
The United States Government As Represented By The Department Of Veterans Affairs


 Inhibitors of bruton's tyrosine kinase patent thumbnailInhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


Compositions and methods for modulating an immune response

Described herein are compositions for increasing il-12 production comprising igg or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing il-12 production comprising an agent that inhibits signaling mediated by interaction between fcrn and igg and uses of said compositions for treating autoimmune diseases.
The Brigham And Women's Hospital, Inc.

A pentacyclic triterpenoid compound with modified structure and preparation method and use thereof

The present invention relates to new pentacyclic triterpenes, their preparation method and use. The compounds of the present invention could effectively treat psoriasis and selectively inhibit in vitro differentiation of the th1 and th17 cells, thereby could be used to treat the th1- or th17-mediated autoimmune diseases..
Suzhou Botany Biomedicals Co., Ltd

Diaryl macrocycles as modulators of protein kinases

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.

Derivatives of polyhydroxy compounds

The present invention relates to novel compounds, e.g. For use as a medicament.
Ratiopharm Gmbh

Prognostic and diagnostic kits and herbal therapies for treating skin conditions, autoimmune diseases, inflammatory ailments and cancer

A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal Ltd.

Prognostic and diagnostic methods and herbal therapies for treating skin conditions, autoimmune diseases, inflammatory ailments and cancer

A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a known or discovered treatment regimen along with periodic doses of an herbal combination including sheng di huang, da huang or jin yin hua or combinations thereof.. .
Sirbal Ltd.

Anti-krs monoclonal antibody and use thereof

The present invention relates to an anti-lysyl-trna synthetase (krs) antibody selectively binding to krs, and a use thereof and, more specifically, to an antibody binding to human krs or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human krs, and enables krs detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ars family, and thus the antibody or fragment thereof can be used to detect krs and diagnose krs-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases..
Medicinal Bioconvergence Research Center

Anti-cd20 antibodies and methods of use

Compositions and methods are provided for treating diseases associated with cd20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-cd20 antibodies capable of binding to a human cd20 antigen located on the surface of a human cd20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (cdc) that is achieved by having at least one optimized cdr engineered within the variable region of the antibody.
Vaccinex, Inc.

Derivative peptide compounds and methods of use

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the polar assortant (pa) peptide, which is a scrambled peptide derived from human astrovirus protein.
Eastern Virginia Medical School

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

Dimeric scaffold peptides comprising hiv-1 gp120 and gp41 epitopes

The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with hcv, hiv, cmv and flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis..
Bionor Immuno As

Pyrrolopyrimidine compounds as kinase inhibitors

Disclosed herein are methods of using pyrrolo[2,3-d]pyrimidine btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, and inflammatory diseases or conditions.. .
Pharmacyclics Llc

Histidyl-trna synthetases for treating autoimmune and inflammatory diseases

The present invention relates generally to compositions and methods comprising histidyl-trna synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to jo-1 antibodies.. .
Pangu Biopharma Limited

Bispecific constructs and their use in the treatment of various diseases

The present invention relates to bispecific constructs that specifically bind to cytotoxic t cells and, simultaneously, to il5r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including the use of the bispecific constructs in treating inflammatory and/or autoimmune diseases and cancer.. .
Numab Ag

Purinone compounds as kinase inhibitors

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Novel aniline derivative, pharmaceutical composition containing same, and use thereof

[solution] the present invention provides a compound represented by the general formula (i): (in the formula, r1, r2 and r3 are each a hydrogen atom, a halogen atom, a c1-6 alkyl group, a halo c1-6 alkyl group or the like, r4 is a c1-6 alkyl group or the like, r5 is a c1-6 alkyl group or the like, r6 is a c1-6 alkyl group or the like, r7 is a hydrogen atom, a halogen atom, a c1-6 alkyl group or the like, r8 is a halogen atom, a c1-6 alkyl group, a halo c1-6 alkyl group, a c1-6 alkoxy group or the like, and r9 is a hydrogen atom or a c1-6 alkyl group.) or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same, and use thereof. The compounds of the present invention have an excellent s1p1 receptor antagonistic activity and therefore are useful as an agent for the treatment or prevention of autoimmune diseases and the like..

Immunomodulatory compositions

The present invention relates to pharmaceutical compositions comprising mesenchymal cells (mscs) and additional agents for blocking co-stimulation of the immune system. The compositions may optionally further comprise a therapeutic cell, a therapeutic tissue, and/or a therapeutic organ implant.
Isletone Ab

Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use

Prodrugs of ibrutinib, pharmaceutical compositions comprising the prodrugs, and methods of using the prodrugs and pharmaceutical compositions for treating autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions are disclosed.. .

Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases

The described invention relates to methods for preventing or treating graft-versus-host disease while preserving a graft-versus-tumor effect, increasing survival of, preserving alloreactivity, or a combination thereof in a patient with a tumor receiving a transplant. The described methods comprise administering to the patient a therapeutic amount of a pharmaceutical composition comprising a rho kinase inhibitor compound, e.g., telmisartan or related angiotensin receptor blockers, and a pharmaceutically acceptable excipient.
Hackensack University Medical Center

Nanoparticle-mediated delivery of cytokines for maintenance of the regulatory t cell phenotype

Compositions for delivery of growth factors needed for stable tregs and methods of use thereof are provided. In preferred embodiments, the compositions can induce, increase, or enhance a functionally robust induced cd4 treg population (e.g., foxp3+ treg) in vivo or ex vivo.
Yale University



Immune Diseases topics:
  • Immune Diseases
  • Autoimmune
  • Immune Disease
  • Autoimmune Disease
  • Autoimmune Diseases
  • Immune Disorder
  • Rheumatoid Arthritis
  • Antibodies
  • Antagonist
  • Nucleotide
  • Proliferative
  • Infectious
  • Infectious Disease
  • Infectious Diseases
  • Type 1 Diabetes


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.8509

    file did exist - file did put3067

    3 - 1 - 58